Efficacy of HA330 Hemoperfusion Adsorbent in Patients Followed in the Intensive Care Unit for Septic Shock and Acute Kidney Injury and Treated with Continuous Venovenous Hemodiafiltration as Renal Replacement Therapy

Abstract

Introduction: Blood purification is an option for treatment of the source of sepsis when correcting patients' septic shock-induced clinical status. We investigated the efficacy of HA330 hemoperfusion adsorbent application with renal replacement therapy in patients with septic shock and acute kidney injury. Methods: This prospective observational study involved 23 patients diagnosed with sepsis who underwent continuous venovenous hemodiafiltration and HA330 hemoperfusion for 2 h once daily for 3 days. The patients' demographic data, comorbidities, lengths of intensive care unit and hospital stays, blood cell counts, blood biochemistry values, coagulation values, blood gas values, inflammatory markers, hemodynamic parameters, and inotropic medication use before and after each application of HA330 hemoperfusion were recorded. The effectiveness of HA330 hemoperfusion was evaluated by comparing the parameters on days 0 and 1, 1 and 2, and 2 and 3. Results: The pH increased significantly following the first application of HA330 hemoperfusion (p = 0.001), the C-reactive protein (CRP) and procalcitonin levels decreased significantly after the second application (p = 0.002 and 0.018, respectively), and the CRP level decreased significantly following the third application (p = 0.046). Conclusions: The application of HA330 hemoperfusion 2 h daily for 3 consecutive days improved level of CRP and heart rate, but had no effect on others or on the prognosis.

Extracorporeal Blood Purification and Organ Support in the Critically Ill Patient during COVID-19 Pandemic: Expert Review and Recommendation

“…However, a recent double-blind RCT found no beneficial effect in ICU patients with MOF [75]. A series of reports have also been published on the utility of hemoperfusion with neutro-macroporous resin device (HA-330/380, Jafron, China) in patients with sepsis [76, 77]. Beneficial effects seem to be related to a significant removal of circulating cytokines.…”

Case Series: Efficacy and Safety of Hemoadsorption With HA-330 Adsorber in Septic Pediatric Patients With Cancer

“…In these clinical settings, a marked reduction of inflammatory mediators, noticeable clinical improvement, and, importantly, no significant side effects were reported (19). Moreover, several reports suggested some benefits from this procedure even in patients affected with septic shock (17,(25)(26)(27). However, large clinical studies on the use of extracorporeal methods in pediatric sepsis are currently missing (17).…”

Kidney Replacement Therapy in COVID-19 Induced Kidney Failure and Septic Shock: A Pediatric Continuous Renal Replacement Therapy [PCRRT] Position on Emergency Preparedness With Resource Allocation

“…In addition, a prospective study of 23 sepsis patients were treated with continuous venovenous hemodiafiltration (CVVHDF) and HA330 hemoperfusion. The investigators reported that all patients showed significant increase in pH and reduction of inflammatory cytokines as indicated by improved levels of C-reactive protein (CRP) (28). However, HA330/HA380 cartridges are not readily available in the United States (US).…”